
Over the past 2 years, four new treatments have entered the treatment zzso for patients with zzso prostate cancer zzso Although these novel agents differ in their mechanism of action, they all face the same challenges: patient selection, timing of therapy and the zzso of their zzso In this review, we will discuss their development and implications when selecting treatment options for zzso zzso 

Over the past few years, a better understanding of the biology of zzso has allowed us to develop rational therapies that have resulted in an improvement in the outcome of prostate cancer zzso zzso has entered the field and despite its limitations and challenges is here to zzso A better understanding of the long-term complications of zzso deprivation has changed the initial approach to most patients with advanced disease, and bone health has become a major focus in their zzso zzso the importance of the zzso zzso and other zzso has led to a dramatic paradigm shift in the treatment of patients with zzso disease in which the zzso zzso becomes a central therapeutic target in the zzso zzso adrenal zzso and engineered super zzso zzso zzso have become the most promising agents in the zzso Similarly, chemotherapy has demonstrated clinical benefit and is now a standard of care in zzso zzso 

The management of zzso patients continues to zzso Novel treatments recently approved by the US Food and Drug Administration have significantly impacted the outcome of zzso With the economic impact of their use, selecting the right patient, defining the appropriate timing and sequence of therapy have become critical facts that need to be followed when defining the contemporary treatment options for men with zzso 

